Profile

Glysantis Inc. is a Canadian biotechnology company developing innovative nanomedicines based on its proprietary NanoDendrix™ platform – safe, monodisperse and biocompatible glycogen nanoparticles. Lead asset GLY-100 is a TLR-targeting immunomodulatory nanoparticle drug aimed at the treatment of solid tumor indications.

Glysantis Inc. Logo

Website

www.glysantis.com

Contact


Event details

Date: June 8 - 12, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

34 in total